Skip to main content
CHE $532.88 -0.80%
CHE logo

CHE · Chemed Corp

Track CHE — free
$532.88 -4.29 (-0.80%) At close · Aug 14
Market Cap
$6.96B
Shares
13.07M
All earnings calls

Earnings call · FY2025 Q4

Chemed Corp Q4 FY2025 Earnings Call

Chemed Corp Q4 FY2025 Earnings Call

Concluded Feb 26, 2026 Audio replay
Feb 26, 2026 57:02 34 turns
Period
FY2025 Q4
Runtime
57:02
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Chemed reported Q4 2025 results that fell short of expectations, with consolidated revenue essentially flat at $639.3 million and GAAP diluted EPS down 9.0% to $5.48; VITAS grew admissions 6.0% but saw margin pressure from acuity mix, while Roto-Rooter revenue fell 3.7% and adjusted EBITDA dropped 21.1% amid a challenging operating environment.

Paid vs. natural search leads 31 VITAS admissions mix rebalancing 26 Water restoration billing and collections 19 Manatee County CON / expansion 10 Commercial business managers 7 2026 guidance and transition year 6

Management tone

Positive

Net tone +15 · moderate hedging

Grounding quotes
  • “The fourth quarter of 2025 fell short of our expectations for both subsidiaries.”
  • “We are very confident that Florida Medicare Cap limitations in 2025 are fully behind us.”
  • “we believe that the difficult operating environment is temporary, and there has not been any impairment in the underlying long-term growth outlook for Roto-Rooter.”
  • “we had a tough quarter, but there is, at least on this side of the line, abundant confidence that the guidance we make is guidance we want to hit.”

Forward guidance

5 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $639.34M -0.1% YoY
Net income · derived Q4 $76.75M -15% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • VITAS admissions increased 6.0% to 17,419 in Q4 2025, with ADC up 1.3% and days-of-care contributing to 1.9% net revenue growth to $418.8 million
  • Florida Medicare Cap position improved by almost $25 million year-over-year, and no Medicare Cap billing limitation was recorded for the Florida combined program in Q4 2025
  • Hospital-based admissions reached 44.8% of total VITAS admissions, described as a post-pandemic high watermark and supportive of sustained long-term Florida stability
  • VITAS granted a certificate of need to operate in Manatee County, Florida, where approximately 3,000 Medicare patients received hospice care in fiscal 2024
  • Roto-Rooter commercial revenue grew 1.6%, with branches having commercial business managers posting 10% revenue increases versus those without
  • Roto-Rooter engaged a new SEO provider in late December focused exclusively on natural search, expected to aid organic lead generation in 2026

Risks & pressure points

  • Q4 consolidated revenue was essentially flat year-over-year and GAAP diluted EPS declined 9.0% to $5.48, with adjusted diluted EPS down 6.0% to $6.42
  • VITAS adjusted EBITDA (excluding Medicare Cap) declined 1.7% to $91.6 million and adjusted EBITDA margin fell 79 basis points to 21.7%, with gross margin (excluding Medicare Cap) down 150 basis points to 27.3%
  • Acuity mix shift negatively impacted VITAS revenue growth by 143 basis points in Q4 2025
  • Roto-Rooter Q4 revenue fell 3.7% to $220.6 million, with net income (excluding discrete items) down 20.6% to $33.8 million and adjusted EBITDA down 21.1% to $47.5 million, a 477 basis point margin decline to 21.5%
  • Roto-Rooter residential revenue declined 3.1%, and water restoration revenue fell 20.0% while implicit price concessions/credit memos rose $4 million (57%) in Q4 2025
  • Total leads were flat year-over-year as rising paid leads (+9.4%) were offset by declining natural leads

Key moments

Jump directly to management's words in the synchronized transcript.

“Our guidance reflects management's belief that 2026 is expected to be a transition year for both VITAS and Roto-Rooter. VITAS's financial results are expected to build over the course of the year as we rebalance our patient mix. We are very confident that Florida Medicare Cap limitations in 2025 are fully behind us.” Kevin McNamara, CEO

Forward guidance

From the 8-K filed Feb 25, 2026.

Metric Guided
VITAS ADC
full year 2026
3.5% – 4%
VITAS EBITDA margin, prior to Medicare Cap
full year 2026
17.5% – 18%
Medicare Cap billing limitations
calendar 2026
$9.5M
Roto-Rooter adjusted EBITDA margin
full year 2026
22.5% – 23%
Full-year 2026 earnings per diluted share, excluding non-cash ex
full-year 2026
$23.25 – $24.25

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Buybacks · derived
$174.56M
Full-screen source Call document